Kura Oncology (KURA) Other Operating Expenses (2010 - 2026)

Kura Oncology (KURA) reported Other Operating Expenses of $262000.0 for Q1 2026, down 98.42% quarter-over-quarter from $16.6 million in Q4 2018.

Kura Oncology (KURA) Other Operating Expenses (2010 - 2026) Analysis & Trends

Kura Oncology (KURA) has 9 years of Other Operating Expenses data on file, last reported at $262000.0 in Q1 2026.

Other Operating Expenses for Q1 2026 came in at $262000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $262000.0 (changed N/A YoY), and the FY2025 annual result was $57000.0, changed N/A from the prior year.
Other Operating Expenses retreated to $262000.0 in Q1 2026 per KURA's latest filing, from $16.6 million in the prior quarter.
Over five years, Other Operating Expenses peaked at $262000.0 in Q1 2026 and troughed at $262000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn
9	Abivax	90.15 Bn	90.15 Bn	-
10	Kura Oncology	802.81 Mn	802.81 Mn	18.00 Mn

Download Data